In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID
Heterobifunctional molecules, such as proteolysis-targeting and autophagy-targeting chimera, represent new drug concepts. They are composed of two protein binders that can induce proximity interactions between two proteins and protein catalysis. Currently, cereblon (CRBN)- and von Hippel-Lindau (VHL)-binders with thalidomide- and VH032-backbones are widely used as E3 ligase binders. Here, we developed a method to validate proteins that interact with heterobifunctional molecules in cells using AirID, a proximity biotinylation enzyme. Interactome of target proteins was validated for six heterobifunctional molecules. ThBD-AirID, a fusion of the thalidomide-binding domain (ThBD) of CRBN and AirID, effectively biotinylated the target proteins. AirID fused to full-length VHL also exhibited highly effective biotinylation. Heterobifunctional molecules with the same target binder but different E3 binders showed different proximity interactome profiles in cells. Analysis using ThBD-AirID revealed a nuclear interaction between androgen receptor and ARV-110. AirID-fused ThBD and VHL could be useful for validating the heterobifunctional molecular interactome in cells.
Authors
- Hiroyuki Yamakoshi (ORCID: https://orcid.org/0000-0002-9263-577X)
- Tatsuya Sawasaki (ORCID: https://orcid.org/0000-0002-7952-0556)
- Satoshi Yamanaka (ORCID: https://orcid.org/0000-0001-8825-7481)
- Aki Kohyama (ORCID: https://orcid.org/0000-0002-3884-858X)
- Hidetaka Kosako (ORCID: https://orcid.org/0000-0003-3228-6368)
- Yoshiharu Iwabuchi (ORCID: https://orcid.org/0000-0002-0679-939X)
- Kohdai Yamada (ORCID: https://orcid.org/0009-0001-9695-8445)
Institutions
- Tohoku University (JP)
- Ehime University (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Communications Biology
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1038/s42003-025-08761-x
- Citations
- 3
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science